Melphalan 100mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation

European Journal of Haematology

Volumn 87, Issue 2, 2011, Pages 117-122

  Blimark, Cecilie ^a   Veskovski, Ljupco ^a   Westin, Jan ^a   Rödjer, Stig ^a   Brune, Mats ^a   Hjorth, Martin ^b   Holmberg, Erik ^c   Andersson, Per Ola ^a   Mellqvist, Ulf Henrik ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Lidkoping Hospital   (Sweden)

^c Centre of Oncology   (Sweden)

Author keywords

100mg m2; Melphalan; Multiple myeloma; Relapse treatment

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ALKYLATING AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BLOOD TOXICITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CELL THERAPY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79960423011     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01634.x     Document Type: Article

References (27)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
2. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11.
3. Blade J, Rosinol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010;115:3655-63.
4. Richardson PG, Schuster MW, Irwin D, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
5. Palumbo AFP, Ambrosini MT, Petrucci MT, Musto P, Caravita T, Pregno P, Bertola A, Cavallo F, Ciccone G, Boccadoro M. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. Eur J Haematol 2005;75:391-5.
6. Dimopoulos MSA, Attal M, Prince HM, Harousseau J, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32.
7. Michael M, Bruns I, Bolke E, Zohren F, Czibere A, Safaian NN, Neumann F, Haas R, Kobbe G, Fenk R. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010;15:13-9.
8. Lee CKBB, Munshi N, Zangari M, Fassas A, Jacobson J. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732-9.
9. Barlogie B, Jagannath S, Dixon DO, Cheson B, Smallwood L, Hendrickson A, Purvis JD, Bonnem E, Alexanian R. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 1990;76:677-80.
10. Lokhorst HM, Sonneveld P, Wijermans PW, van Marwijk Kooy M, Meuwissen OJ, van Oers RH, van der Griend R, Dekker AW. Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma. Br J Haematol 1996;92:44-8.
11. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, Omede P, Tarella C, Pileri A, Boccadoro M. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999;94:1248-53.
12. Krejci M, Adam Z, Buchler T, et al. Salvage treatment with upfront melphalan 100mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma. Ann Hematol 2010;89:483-7.
13. Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009;43:417-22.
14. Palumbo A, Avonto I, Bruno B, et al. Intermediate-dose melphalan (100mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma. Clin Lymphoma Myeloma 2006;6:475-7.
15. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
16. Alvares CL, Davies FE, Horton C, Patel G, Powles R, Morgan GJ. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006;91:141-2.
17. Lee CK, Barlogie B, Zangari M, et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002;30:873-8.
18. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006;106:1084-9.
19. Lonial S. Relapsed Multiple Myeloma. Hematology Am Soc Hematol Educ Program 2010;2010:303-9.
20. Ludwig H, Beksac M, Blade J, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010;15:6-25.
21. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:57-65.
22. Kumar SKRS, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
23. Weber DMCC, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42.
24. Stadtmauer EAWD, Niesvizky R, Belch A, Prince MH, San Miguel JF, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009;82:426-32.
25. Mikhael JR, Zadeh S, Samiee S, et al. Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relapsed multiple myeloma: Improved outcomes in patients with longer disease free interval after first ASCT. Blood 2007;110. (ASH Annual Meeting Abstracts): Abstract 946.
26. Sirohi B, Powles R, Rudin C, Singhal S, Kulkarni S, Saso R, Horton C, Mehta J, Treleaven J. Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft. Hematology 2005;10:361-4.
27. Novitzky N, Thomson J, Thomas V, du Toit C, Mohamed Z, McDonald A. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma. Biol Blood Marrow Transplant 2010;16:1402-10.